Mission Statement, Vision, & Core Values (2026) of The United Laboratories International Holdings Limited.

Step into the world of The United Laboratories International Holdings Limited-founded in 1990 and operating across seven production bases that span pharmaceutical intermediates, bulk medicines, finished products, veterinary drugs, empty capsules and medical devices-where a global sales network reaching nearly 80 countries and regions supports a company that reported HKD 2.2 billion in revenue for the year ended December 31, 2022 (a 10% year‑on‑year increase) and achieved an enterprise value of USD 17.88 billion in 2025; guided by the mission "Make Life More Valuable," a vision to be "a model in the pharmaceutical industry," and core values of Kind, Conscientious, Diligent and Highly‑efficient-combined with pragmatism, scientific rigor, innovation, friendship, equality, joint development and a clear commitment to environmental protection-the company's integrated R&D platforms across biological, chemical and animal healthcare research and its portfolio spanning anti‑infectives, diabetes and ophthalmology invite a closer look at how these pillars translate into patents, sustainable investments and international strategic partnerships.

The United Laboratories International Holdings Limited (3933.HK) - Intro

• Founded: 1990
• Production bases: 7 (intermediates, APIs, finished dosage forms, veterinary, empty capsules, medical devices)
• Global footprint: ~80 countries/regions

• Deliver safe, effective and affordable pharmaceuticals to patients worldwide.
• Advance public health through continual scientific innovation and responsible manufacturing.
• Create long-term value for stakeholders while upholding high ethical and compliance standards.

• Be a top-tier global pharmaceutical enterprise recognized for innovation, quality and sustainability.
• Expand therapeutic reach and product portfolio through targeted R&D, strategic partnerships and market expansion.
• Achieve leadership in selected therapeutic segments and manufacturing capabilities.

• Scientific excellence: rigorous R&D and evidence-based development.
• Quality and compliance: stringent manufacturing standards and regulatory adherence.
• Patient-centricity: prioritizing safety, accessibility and therapeutic outcomes.
• Integrity and transparency: ethical conduct across operations and supply chains.
• Sustainability: environmental stewardship and long-term social responsibility.

• R&D investment: sustained allocation toward drug discovery, formulation optimization and regulatory submissions to broaden pipeline and enhance product competitiveness.
• Manufacturing scale & diversification: leveraging seven specialized production bases to reduce supply risk and improve margin capture across product segments.
• Global commercialization: expanding distribution channels and market access in nearly 80 jurisdictions to capture geographic growth and diversify revenue streams.
• Quality & compliance systems: continuous improvement programs and certification efforts to meet international GMP, ISO and regulatory requirements.
• ESG & sustainability initiatives: operational efficiency, waste reduction and community health programs aligned with long‑term value creation.

The United Laboratories International Holdings Limited (3933.HK) - Overview

Mission Statement - 'Make Life More Valuable': a concise articulation of The United Laboratories International Holdings Limited (3933.HK)'s purpose to improve quality of life by producing safe, effective medicines and advancing public health through innovation, diversified therapeutics and social responsibility.

• Focus areas: anti-infective drugs, diabetes care, ophthalmology and other therapeutic segments.
• R&D orientation: development of new molecular entities, formulation improvements and biologics support with multiple national-level patents.
• Social commitment: investments in environmental protection, education, poverty alleviation and community welfare projects.

How the mission guides operations and measurable outcomes:

• Product safety and quality: adherence to GMP standards across manufacturing sites and regular product safety monitoring.
• Therapeutic diversification: pipeline and marketed portfolio span acute and chronic disease treatments to address broad public-health needs.
• Innovation metrics: sustained R&D spend, patent filings and technology transfer partnerships to commercialize scientific achievements.
• Corporate social responsibility: quantified charitable donations, environmental capital expenditures and community programs.

Vision - long-term direction and strategic ambitions:

• Becoming a leading integrated healthcare company recognized for product quality, therapeutic impact and innovation.
• Expanding global reach through export markets and international partnerships while maintaining regulatory compliance and safety.
• Enhancing shareholder value via sustainable growth, margin improvement and disciplined capital allocation.

Core Values - principles that operationalize the mission and vision:

• Patient-first ethic: prioritize efficacy and safety in product development and lifecycle management.
• Scientific rigor and innovation: evidence-based R&D, continuous improvement and protection of intellectual property.
• Integrity and compliance: strict adherence to regulatory standards and ethical business conduct.
• Social responsibility: measurable investment in community welfare, environmental stewardship and employee development.
• Collaboration: partnerships with academic institutions, hospitals and industry peers to accelerate therapeutic solutions.

Selected performance indicators linking values to outcomes:

• R&D intensity: R&D as % of revenue ~5.6% (latest fiscal year), supporting new product approvals and patent filings.
• Return on equity (ROE): ~11% (latest fiscal year), reflecting profitability and capital efficiency.
• Product approvals: multiple new product registrations in ophthalmology and diabetes care across the past 3 years.
• Sustainability metrics: reductions in specific emissions and increased recycling rates following environmental CapEx.

Stakeholder engagement and transparency:

• Regular investor communications and governance disclosures aligned with Hong Kong Exchange requirements.
• Community outreach programs targeting underserved regions and public-health education campaigns.
• Ongoing dialogue with regulators, suppliers and clinical partners to ensure product access and quality assurance.

Further reading: Exploring The United Laboratories International Holdings Limited Investor Profile: Who's Buying and Why?

The United Laboratories International Holdings Limited (3933.HK) - Mission Statement

• Manufacture first-class products: continuous improvement of quality systems (GMP, ISO), expanded biologics and chemical drug pipelines.
• Provide first-class service: enhanced market access, patient support programs, and regulatory compliance across jurisdictions.
• Cultivate first-class professionals: talent development, industry collaborations, and multidisciplinary R&D teams.

• Comprehensive R&D platforms: biological R&D, chemical drug R&D, and animal healthcare R&D - each managed as dedicated, cross-functional centers.
• Global expansion: strategic cooperation with international partners to broaden distribution, licensing, and co-development.
• Environmental stewardship: integrating green manufacturing practices and emission controls to preserve "green mountains, lucid water, blue sky, and white clouds."
• Patient-centered outcomes: prioritizing therapies and animal health solutions that demonstrably improve life value.

• Preclinical programs: 12+ candidates across biologics and chemical entities, with several vaccine/adjuvant collaborations in development.
• Clinical programs: 4 ongoing clinical-stage projects (Phase I-II), focusing on oncology-supportive care and veterinary therapeutics.
• Patents & IP: 60+ active patents and pending filings in core technologies and formulations.

• Carbon intensity reduction: target to reduce scope 1+2 emissions by 30% by 2030 (baseline FY2022).
• Wastewater recycling: >50% of facility process water to be recycled by 2028.
• Compliance: zero major regulatory sanctions in the past 5 years; continued investment in compliance systems.

The United Laboratories International Holdings Limited (3933.HK): Vision Statement

• Kind, Conscientious, Diligent and Highly-efficient - embedding professionalism and operational excellence across manufacturing, supply chain, and commercialization.
• Pragmatic and Rigorous; Scientific Truth-seeking; Future-oriented and Innovative - prioritizing evidence-based R&D, continuous process optimization, and next-generation therapeutic development.
• Friendship, Equality and Joint Development - fostering collaborative partnerships across industry, academia, suppliers and community stakeholders.
• Environmental protection - committed to producing safe medicines while preserving "green mountains, lucid water, blue sky and white clouds."

• R&D prioritization: The "Scientific Truth-seeking" and "Innovative" values translate into sustained R&D budgeting (≈6% of revenue) focused on high-value formulations and process innovations to shorten time-to-market and improve therapeutic profiles.
• Operational excellence: "Diligent and Highly-efficient" guides lean manufacturing, yielding utilization rates above industry averages and supporting margins that sustained net profit of HK$720M in FY2023.
• Sustainable growth: Environmental commitments inform capital allocation-investments in wastewater treatment, solvent recovery and renewable energy projects to meet the 2030 emission target while protecting community health.
• Inclusive partnerships: "Friendship, Equality and Joint Development" fosters licensing, co-development and OEM relationships that underpin roughly 40% of revenue from exports and international channels.

• Product safety and compliance: Routine GMP audits, batch-level traceability and pharmacovigilance systems ensure alignment with "Kind" and patient-first commitments.
• Investment criteria: Capital projects are screened for scientific rigor, ROI, and environmental impact-balancing innovation with pragmatic risk management.
• People and culture: Recruitment, training and performance metrics emphasize conscientious behavior, efficiency, and collaborative development across levels.
• Transparency and reporting: Regular ESG disclosures and financial reporting align with the company's vision of being a reliable steward for investors and communities.